Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 3, 2016, Pages 347-348

  Jardim Perassi, Bruna Victorasso ^a   Lourenço, Mateus Repolês ^a   Doho, Gabriel Mandarini ^a   Grígolo, Ingrid Helen ^a   Gelaleti, Gabriela Bottaro ^a,b   Ferreira, Lívia Carvalho ^a,b   Borin, Thaiz Ferraz ^a,c   Moschetta, Marina Gobbe ^a,c   de Campos Zuccari, Debora Aparecida Pires ^a,c  

^a Laboratório de Investigação Molecular no Câncer LIMC   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

Angiogenesis; Breast neoplasms; Cell hypoxia; Cell line; Gene expression; Melatonin; Vascular endothelial growth factors

Indexed keywords

ANGIOGENIC FACTOR; MELATONIN; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANTIOXIDANT; CYTOKINE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLT4 PROTEIN, HUMAN; GELATINASE B; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KDR PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PANCREATIC RIBONUCLEASE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VEGFA PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ANALYSIS OF VARIANCE; ANGIOGENESIS; ARTICLE; BREAST CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOCYTOCHEMISTRY; MTT ASSAY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BREAST TUMOR; CELL HYPOXIA; CELL SURVIVAL; DRUG EFFECTS; FEMALE; MCF-7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIOXIDANTS; BREAST NEOPLASMS; CELL HYPOXIA; CELL SURVIVAL; CYTOKINES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MELATONIN; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84958986256     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150511094201     Document Type: Article

References (96)

1. Arbab, A. S. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol. Histopathol., 2012, 27(5), 549-557.
2. Weis, S. M.; Cheresh, D. A. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat. Med., 2011, 17(11), 1359-1370.
3. Dai, M.; Cui, P.; Yu, M.; Han, J.; Li, H.; Xiu, R. Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J. Pineal. Res., 2008, 44(2), 121-126.
4. Weidner, N. Tumor angiogenesis: Review of current applications in tumor prognostication. Semin. Diagn. Pathol., 1993, 10(4), 302-313.
5. Gacche, R. N.; Meshram, R. J. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog. Biophys. Mol. Biol., 2013, 113(2), 333-354.
6. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.
7. Sakurai, T.; Kudo, M. Signaling pathways governing tumor angiogenesis. Oncology, 2011, 81 Suppl 1, 24-29.
8. Mole, D. R.; Ratcliffe, P. J. Cellular oxygen sensing in health and disease. Pediatr. Nephrol., 2008, 23(5), 681-694.
9. Coulon, S.; Heindryckx, F.; Geerts, A.; Van Steenkiste, C.; Colle, I.; Van Vlierberghe, H. Angiogenesis in chronic liver disease and its complications. Liver Int., 2011, 31(2), 146-162.
10. Schaafhausen, M. K.; Yang, W. J.; Centanin, L.; Wittbrodt, J.; Bosserhoff, A.; Fischer, A.; Schartl, M.; Meierjohann, S. Tumor angiogenesis is caused by single melanoma cells in a manner dependent on reactive oxygen species and NF-kappaB. J. Cell Sci., 2013, 126(Pt 17), 3862-3872.
11. Volkova, E.; Robinson, B. A.; Willis, J.; Currie, M. J.; Dachs, G. U. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett., 2014, 7(2), 311-320.
12. Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
13. Costa, C.; Soares, R.; Schmitt, F. Angiogenesis: Now and then. APMIS, 2004, 112(7-8), 402-412.
14. Buchanan, C. F.; Szot, C. S.; Wilson, T. D.; Akman, S.; Metheny-Barlow, L. J.; Robertson, J. L.; Freeman, J. W.; Rylander, M. N. Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro. J. Cell Biochem., 2012, 113(4), 1142-1151.
15. Tait, C. R.; Jones, P. F. Angiopoietins in tumours: The angiogenic switch. J. Pathol., 2004, 204(1), 1-10.
16. Metheny-Barlow, L. J.; Li, L. Y. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res., 2003, 13(5), 309-317.
17. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801), 249-257.
18. Liotta, L. A.; Kohn, E. C. The microenvironment of the tumour-host interface. Nature, 2001, 411(6835), 375-379.
19. Korah, R. M.; Sysounthone, V.; Golowa, Y.; Wieder, R. Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res., 2000, 60(3), 733-740.
20. Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell, 2005, 7(6), 513-520.
21. Nikitenko, L. L. Vascular endothelium in cancer. Cell Tissue Res., 2009, 335(1), 223-240.
22. Sasaki, T.; Hiroki, K.; Yamashita, Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed. Res Int., 2013, 2013, 546318.
23. Luchetti, F.; Canonico, B.; Betti, M.; Arcangeletti, M.; Pilolli, F.; Piroddi, M.; Canesi, L.; Papa, S.; Galli, F. Melatonin signaling and cell protection function. FASEB J., 2010, 24(10), 3603-3624.
24. Reiter, R. J. Mechanisms of cancer inhibition by melatonin. J. Pineal. Res., 2004, 37(3), 213-214.
25. Carrillo-Vico, A.; Guerrero, J. M.; Lardone, P. J.; Reiter, R. J. A review of the multiple actions of melatonin on the immune system. Endocrine, 2005, 27(2), 189-200.
26. Proietti, S.; Cucina, A.; Reiter, R. J.; Bizzarri, M. Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol. Life Sci., 2013, 70(12), 2139-2157.
27. Lissoni, P.; Rovelli, F.; Malugani, F.; Bucovec, R.; Conti, A.; Maestroni, G. J. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro. Endocrinol. Lett., 2001, 22(1), 45-47.
28. Cui, P.; Luo, Z.; Zhang, H.; Su, Y.; Li, A.; Li, H.; Zhang, J.; Yang, Z.; Xiu, R. Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J. Pineal. Res., 2006, 41(4), 358-362.
29. Kaur, C.; Sivakumar, V.; Lu, J.; Ling, E. A. Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland. J. Pineal. Res., 2007, 42(4), 338-349.
30. Park, J. W.; Hwang, M. S.; Suh, S. I.; Baek, W. K. Melatonin downregulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J. Pineal. Res., 2009, 46(4), 415-421.
31. Alvarez-Garcia, V.; Gonzalez, A.; Alonso-Gonzalez, C.; Martinez-Campa, C.; Cos, S. Antiangiogenic effects of melatonin in endothelial cell cultures. Microvasc. Res., 2013, 87, 25-33.
32. Alvarez-Garcia, V.; Gonzalez, A.; Alonso-Gonzalez, C.; Martinez-Campa, C.; Cos, S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J. Pineal. Res., 2013, 54(4), 373-380.
33. Jardim-Perassi, B. V.; Arbab, A. S.; Ferreira, L. C.; Borin, T. F.; Varma, N. R.; Iskander, A. S.; Shankar, A.; Ali, M. M.; De Campos Zuccari, D. A. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PloS One, 2014, 9(1), e85311.
34. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25(4), 402-408.
35. Ram, P. T.; Yuan, L.; Dai, J.; Kiefer, T.; Klotz, D. M.; Spriggs, L. L.; Hill, S. M. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. J. Pineal. Res., 2000, 28(4), 210-218.
36. Mao, L.; Yuan, L.; Xiang, S.; Zeringue, S. B.; Dauchy, R. T.; Blask, D. E.; Hauch, A.; Hill, S. M. Molecular deficiency(ies) in MT(1) melatonin signaling pathway underlies the melatonin-unresponsive phenotype in MDA-MB-231 human breast cancer cells. J. Pineal. Res., 2014, 56(3), 246-253.
37. Jung, J. H.; Sohn, E. J.; Shin, E. A.; Lee, D.; Kim, B. Jung, D. B.; Kim, J. H.; Yun, M.; Lee, H. J.; Park, Y. K.; Kim, S. H. Melatonin suppresses the expression of 45s preribosomal rna and upstream binding factor and enhances the antitumor activity of puromycin in mda-mb-231 breast cancer cells. Evid. Based Compl. Alternat. Med., 2013, 2013, 879746.
38. Leman, E. S.; Sisken, B. F.; Zimmer, S.; Anderson, K. W. Studies of the interactions between melatonin and 2 Hz, 0. 3 mT PEMF on the proliferation and invasion of human breast cancer cells. Bioelectromagnetics, 2001, 22(3), 178-184.
39. Sanchez-Hidalgo, M.; Lee, M.; de la Lastra, C. A.; Guerrero, J. M.; Packham, G. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J. Pineal Res., 2012, 53(4), 366-373.
40. Yerneni, L. K.; Jayaraman, S. Pharmacological action of high doses of melatonin on B16 murine melanoma cells depends on cell number at time of exposure. Melanoma Res., 2003, 13(2), 113-711.
41. Dubocovich, M. L.; Delagrange, P.; Krause, D. N.; Sugden, D.; Cardinali, D. P.; Olcese, J. International union of basic and clinical pharmacology. lxxv. nomenclature, classification, and pharmacology of g protein-coupled melatonin receptors. Pharmacol Rev., 2010, 62(3), 343-380.
42. Juszczak, M.; Roszczyk, M.; Kowalczyk, E.; Stempniak, B. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin(4-P-PDOT), on melatonindependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies. J. Physiol. Pharmacol., 2014, 65(6), 777-784.
43. Maestroni, G. J.; Conti, A. Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status. Lab. Invest., 1996, 75(4), 557-561.
44. Ekmekcioglu, C. Expression and putative functions of melatonin receptors in malignant cells and tissues. Wien. Med. Wochenschr., 2014, 164(21-22), 472-478.
45. Zeitzer, J. M.; Daniels, J. E.; Duffy, J. F.; Klerman, E. B.; Shanahan, T. L.; Dijk, D. J.; Czeisler, C. A. Do plasma melatonin concentrations decline with age? Am. J. Med., 1999, 107(5), 432-436.
46. Zawilska, J. B.; Skene, D. J.; Arendt, J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol. Rep., 2009, 61(3), 383-410.
47. Proietti, S.; Carlomagno, G.; Dinicola, S.; Bizzarri, M. Soft gel capsules improve melatonin's bioavailability in humans. Exp. Opin. Drug Metab. Toxicol., 2014, 10(9), 1193-1198.
48. Arendt, J.; Skene, D. J. Melatonin as a chronobiotic. Sleep Med. Rev., 2005, 9(1), 25-39.
49. Peng, H. T.; Bouak, F.; Vartanian, O.; Cheung, B. A physiologically based pharmacokinetics model for melatonin-effects of light and routes of administration. Int. J. Pharm., 2013, 458(1), 156-168.
50. Waldhauser, F.; Waldhauser, M.; Lieberman, H. R.; Deng, M. H.; Lynch, H. J.; Wurtman, R. J. Bioavailability of oral melatonin in humans. Neuroendocrinology, 1984, 39(4), 307-313.
51. Lissoni, P.; Barni, S.; Meregalli, S.; Fossati, V.; Cazzaniga, M.; Esposti, D.; Tancini, G. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br. J. Cancer, 1995, 71(4), 854-856.
52. Lissoni, P.; Paolorossi, F.; Tancini, G.; Ardizzoia, A.; Barni, S.; Brivio, F.; Maestroni, G. J.; Chilelli, M. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Br. J. Cancer, 1996, 74(9), 1466-1468.
53. Barni, S.; Lissoni, P.; Paolorossi, F.; Crispino, S.; Archili, C.; Tancini, G. A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant tofluorouracil plus folates. Tumori., 1990, 76(1), 58-60.
54. Lissoni, P.; Barni, S.; Ardizzoia, A.; Paolorossi, F.; Crispino, S.; Tancini, G.; Tisi, E.; Archili, C.; De Toma, D.; Pipino, G.; Conti, A.; Maestroni, G. J. M. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced non small cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology, 1992, 49(5), 336-339.
55. Chava, V. K.; Sirisha, K. Melatonin: A novel indolamine in oral health and disease. Int. J. Dent., 2012, 720185.
56. Di Bella, G.; Mascia, F.; Gualano, L.; Di Bella, L. Melatonin anticancer effects: Review. Int. J. Mol. Sci., 2013, 14(2), 2410-2430.
57. Sanchez-Barcelo, E. J.; Cos, S.; Fernandez, R.; Mediavilla, M. D. Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer, 2003, 10(2), 153-159.
58. Mediavilla, M. D.; Sanchez-Barcelo, E. J.; Tan, D. X.; Manchester, L.; Reiter, R. J. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem., 2010, 17(36), 4462-4481.
59. Liu, Q.; Xu, Z.; Mao, S.; Chen, W.; Zeng, R.; Zhou, S.; Liu J. Effect of hypoxia on hypoxia inducible factor-1α, insulin-like growth factor I and vascular endothelial growth factor expression in hepatocellular carcinoma HepG2 cells. Oncol Lett., 2015, 9(3), 1142-1148.
60. Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001, 294(5545), 1337-1340.
61. Park, S. Y.; Jang, W. J.; Yi, E. Y.; Jang, J. Y.; Jung, Y.; Jeong, J. W.; Kim, Y. J. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J. Pineal. Res., 2010, 48(2), 178-184.
62. Semenza, G. L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 2010, 29(5), 625-634.
63. Dai, Z. J.; Gao, J.; Ma, X. B.; Yan, K.; Liu, X. X.; Kang, H. F.; Ji, Z. Z.; Guan, H. T.; Wang, X. J. Up-regulation of hypoxia inducible factor-1alpha by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. J. Exp. Clin. Cancer Res., 2012, 31, 28.
64. Carbajo-Pescador, S.; Ordonez, R.; Benet, M.; Jover, R.; Garcia-Palomo, A.; Mauriz, J. L.; Gonzalez-Gallego, J. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br. J. Cancer, 2013, 109(1), 83-91.
65. Chang, Y. H.; Jiang, M.; Liu, K. G.; Li, X. Q. Curcumin inhibited hypoxia induced epithelial-mesenchymal transition in hepatic carcinoma cell line HepG2 in vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2013, 33(8), 1102-1106.
66. Xu, L. F.; Ni, J. Y.; Sun, H. L.; Chen, Y. T.; Wu, Y. D. Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells. World J. Gastroenterol., 2013, 19(11), 1749-1759.
67. Xu, G.; Bai, X.; Wang, M.; Xie, W.; Li, R.; Li, C. Characterization of glycolytic phenotype of SHG44 human glioma cells under hypoxic conditions and its association with cell proliferation and apoptosis. Nan Fang Yi Ke Da Xue Xue Ba o, 2013, 33(3), 406-411.
68. Goncalves, N. N.; Rodrigues, R. V.; Jardim-Perassi, B. V.; Moschetta, M. G.; Lopes, J. R.; Colombo, J.; Zuccari, D. A. Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. Anticancer Agents Med. Chem., 2014, 14 (9), 1302-1311.
69. Zhang, Y.; Liu, Q.; Wang, F.; Ling, EA.; Liu, S.; Wang, L.; Yang, Y.; Yao, L.; Chen. X.; Wang, F.; Shi, W.; Gao, M.; Hao, A. Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1α. J. Pineal. Res., 2013, 55(2), 121-130.
70. Cho, S. Y.; Lee, H. J.; Jeong, S. J.; Lee, H. J.; Kim, H. S.; Chen, C. Y.; Lee, E. O.; Kim, S. H. Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells. J. Pineal. Res., 2011, 51(1), 87-93.
71. Kim, K. J.; Choi, J. S.; Kang, I.; Kim, K. W.; Jeong, C. H.; Jeong, J. W. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J. Pineal. Res., 2013, 54(3), 264-270.
72. Matsuura, M.; Onimaru, M.; Yonemitsu, Y.; Suzuki, H.; Nakano, T.; Ishibashi, H.; Shirasuna, K.; Sueishi, K. Autocrine loop between vascular endothelial growth factor(VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am. J. Pathol., 2009, 175(4), 1709-1721.
73. Woolard, J.; Wang, W. Y.; Bevan, H. S.; Qiu, Y.; Morbidelli, L.; Pritchard-Jones, R. O.; Cui, T. G.; Sugiono, M.; Waine, E.; Perrin, R.; Foster, R.; Digby-Bell, J.; Shields, J. D.; Whittles, C. E.; Mushens, R. E.; Gillatt, D. A.; Ziche, M.; Harper, S. J.; Bates, D. O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res., 2004, 64(21), 7822-7835.
74. Price, D. J.; Miralem, T.; Jiang, S.; Steinberg, R.; Avraham, H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ., 2001, 12(3), 129-135.
75. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 2005, 23(5), 1011-1127.
76. Weigand, M.; Hantel, P.; Kreienberg, R.; Waltenberger, J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis, 2005, 8(3), 197-204.
77. Dias, S.; Choy, M.; Alitalo, K.; Rafii, S. Vascular endothelial growth factor(VEGF)-C signaling through FLT-4(VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood, 2002, 99(6), 2179-2184.
78. Masood, R.; Kundra, A.; Zhu, S.; Xia, G.; Scalia, P.; Smith, D. L.; Gill, P. S. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer., 2003, 104(5), 603-610.
79. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103(2), 211-225.
80. Margheri, M.; Pacini, N.; Tani, A.; Nosi, D.; Squecco, R.; Dama, A.; Masala, E.; Francini, F.; Zecchi-Orlandini, S.; Formigli, L. Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. Eur. J. Pharmacol., 2012, 681(1-3), 34-43.
81. Blask, D. E.; Sauer, L. A.; Dauchy, R. T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem., 2002, 2(2), 113-132.
82. Campo, L.; Turley, H.; Han, C.; Pezzella, F.; Gatter, K. C.; Harris, A. L.; Fox, S. B. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J. Pathol., 2005, 205(5), 585-591.
83. Tello-Montoliu, A.; Patel, J. V.; Lip, G. Y. Angiogenin: A review of the pathophysiology and potential clinical applications. J. Thromb. Haemost., 2006, 4(9), 1864-1874.
84. Ramani, P.; Headford, A.; Sowa-Avugrah, E.; Hunt, L. P. Angiogenin expression in human kidneys and Wilms' tumours: relationship with hypoxia and angiogenic factors. Int. J. Exp. Pathol., 2013, 94(2), 115-125.
85. Li, S.; Hu, G. F. Angiogenin-mediated rRNA transcription in cancer and neurodegeneration. Int. J. Biochem. Mol. Biol., 2010, 1(1), 26-35.
86. Dutta, S.; Bandyopadhyay, C.; Bottero, V.; Veettil, M. V.; Wilson, L.; Pins, M. R.; Johnson, K. E.; Warshall, C.; Chandran, B. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. Mol. Oncol., 2014, 8(3), 483-507.
87. Kishimoto, K.; Yoshida, S.; Ibaragi, S.; Yoshioka, N.; Okui, T.; Hu, G. F.; Sasaki, A. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer. Oral Oncol., 2012, 48(11), 1120-1127.
88. Ang, J.; Sheng, J.; Lai, K.; Wei, S.; Gao, X. Identification of estrogen receptor-related receptor gamma as a direct transcriptional target of angiogenin. PloS one, 2013, 8(8), e71487.
89. Nilsson, U. W.; Abrahamsson, A.; Dabrosin, C. Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy reduces breast cancer growth in vivo. Clin. Cancer Res., 2010, 16(14), 3659-3669.
90. Piccoli, R.; Olson, K. A.; Vallee, B. L.; Fett, J. W. Chimeric antiangiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc. Natl. Acad. Sci. USA, 1998, 95(8), 4579-4583.
91. Distler, J. H.; Hirth, A.; Kurowska-Stolarska, M.; Gay, R. E.; Gay, S.; Distler, O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med., 2003, 47(3), 149-161.
92. Ordonez, R.; Carbajo-Pescador, S.; Prieto-Dominguez, N.; Garcia-Palomo, A.; Gonzalez-Gallego, J.; Mauriz, J. L. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J. Pineal. Res., 2014, 56(1), 20-30.
93. Rudra, D. S.; Pal, U.; Maiti, N. C.; Reiter, R. J.; Swarnakar, S. Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J. Pineal. Res., 2013, 54(4), 398-405.
94. Qin, W.; Lu, W.; Li, H.; Yuan, X.; Li, B.; Zhang, Q.; Xiu, R. Melatonin inhibits IL1beta-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NFkappaB activation. J. Endocrinol., 2012, 214(2), 145-153.
95. Wang, J.; Hao, H.; Yao, L.; Zhang, X.; Zhao, S.; Ling, E. A.; Hao, A.; Li, G. Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J. Pineal. Res., 2012, 53(2), 180-187.
96. Di, G. H.; Lu, J. S.; Song, C. G.; Li, H. C.; Shen, Z. Z.; Shao, Z. M. Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas. J. Exp. Clin. Cancer Res., 2005, 24(4), 601-607.